ASCO 2025
Stay up-to-date on the latest news, research updates, and presentations in GI cancer treatment from the ASCO 2025 Annual Meeting.
Results of CASSANDRA may alter the standard of care for patients with resectable PDAC.
Dr. Reni breaks a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG for stage I-III PDAC.
Adjuvant nivolumab provides durable long-term DFS benefit and shows an OS advantage in patients with resected EC/GEJC.
Long-term follow-up from KEYNOTE-016 explores pembrolizumab treatment in dMMR/MSI-H solid tumors in advanced CRC.
The addition of concurrent chemoradiation to chemotherapy can improve OS and resection rates in patients with LAGBC.
The Claudin18.2 antibody-drug conjugate IBI343 is well tolerated and shows encouraging efficacy in patients with PDAC.
LEAP-002 long-term follow-up suggests there may be benefit associated with len/pembro for patients with aHCC.
Sotorasib with panitumumab and FOLFIRI has shown promising long-term efficacy results in pretreated KRAS G12C–mutated ...
Researchers evaluated the efficacy and safety of hepatic arterial infusion chemotherapy as a first-line treatment option.
Pembro plus lenvatinib with chemo may improve progression-free survival in patients when compared with the standard of care.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.